Claims for Patent: 6,087,476

Summary for Patent: 6,087,476

Title:	Luminescent chimeric proteins
Abstract:	The invention relates to luminescent chimeric proteins which include a photoprotein and a second protein which may be light- or heavy-chain immunoglobulin, an antigenic peptide, avidin, streptavidin, or protein A. The invention also relates to chimeric protein genes, plasmids containing said gene, and hosts transformed with said plasmid. The invention also relates to a range of highly sensitive immunoassays which use the chimeric proteins.
Inventor(s):	Kenten; John H. (Gaithersburg, MD), Casadei; Jan (Bethesda, MD), Powell; Michael J. (Gaithersburg, MD)
Assignee:	IGEN International, Inc. (Gaithersburg, MD)
Application Number:	08/906,654
Patent Claims:	1. A luminescent chimeric protein comprising a continuous polypeptide sequence having a first protein sequence and a second protein sequence, wherein (i) said continuous polypeptide sequence is composed of a linear sequence of amino acid residues covalently linked to each other through amide linkages and terminating at one end of said continuous polypeptide sequence with a terminal carboxylic acid group; (ii) said first protein sequence and said second protein sequence are covalently linked together through an amide linkage connecting an amino acid residue of said first protein sequence with an amino acid residue of said second protein sequence; (iii) said first protein sequence is a luciferase photoprotein selected from the group consisting of aequorin, obelin, mnemiopsin, and berovin; (iv) said second protein sequence is an amino acid sequence of an antigen-specific protein selected from the group consisting of light-chain immunoglobulin, heavy-chain immunoglobulin, avidin, streptavidin, protein A, an antigenic peptide, and an antigenically active fragment of said antigenic peptide; (v) said continuous polypeptide sequence exhibits both luminescent properties attributable to said luciferase photoprotein and antigen recognition properties attributable to said antigen-specific protein; and (vi) said continuous polypeptide sequence having been produced by protein expression using a recombinantly produced DNA gene construct. 2. The luminescent chimeric protein of claim 1, wherein said second protein sequence is an amino acid sequence of an antigen specific heavy chain immunoglobulin and said luciferase photoprotein has replaced a portion of said immunoglobulin. 3. The luminescent chimeric protein of claim 1, wherein said second protein sequence is an amino acid sequence of an antigen specific heavy chain immunoglobulin and said luciferase photoprotein has replaced the F.sub.c portion of said immunoglubulin. 4. The luminescent chimeric protein of claim 1, wherein said second protein sequence is a remnant of an amino acid sequence comprising the V.sub.H and CH-1 domains of an antigen-specific immunoglobulin. 5. The luminescent chimeric protein of claim 1 wherein said antigenic peptide and said antigenically active fragment of aid antigenic peptide are selected from the group consisting of the HIV diagnostic peptides p18, p24, gp41 and gp120, atrial natriuretic factor, the HCG diagnostic peptides, angiotensin-II, renin, insulin, glucagon, parathyroid hormone, thyroid stimulating hormone, follicle stimulating hormone, human chorionic gonadatropin, thryotropin-releasing hormone (TRH), gonadotropin-releasing hormone (GnRH), LH-releasing hormone (LHRH), corticotropin-releasing hormone (CRH), growth hormone-releasing hormone (GHRH), somatostatin (SS), growth hormone-inhibiting hormone (GHIH), thyrotropin, thyroid stimulating hormone (TSH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), growth hormone (GH), somatotropin, .beta.-lipotropin (.beta.-LPH), corticotropin, adenocorticotropin (ACTH), .beta.-endorphin (.beta.-END), .alpha.-melancycle stimulating hormone (.alpha.-MSH), leu-enkephalin (LEK), met-enkephalin (MEK), vasopressin, antidiuretic hormone (ADH), oxytocin, parathyroid hormone (PTH), parathormone, relaxin, inhibin, pancreatic polypeptide, gastrin, secretin, cholecystokinin-pancreozymin (CCK-PZ), motilin, vasoactive intestinal peptide (VIP), gastric inhibitory polypeptide (GIP), bombesin, neurotensin, substance P (SP), and hepatitis surface antigen.

Details for Patent 6,087,476

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2008-03-24